Abstract 37P
Background
Novel agents, such as immunotherapies, are likely to cause late-onset toxicities. The inclusion of these toxicities can lead to prolonged trials since traditional phase I designs require full follow-up information for each participant. TITE-CRM, an extension of the CRM design, permits continuous recruitment of participants by incorporating incomplete follow-up data to determine the recommended dose for the next participant. Thus, it can shorten trial duration, but it may also treat participants at suboptimal doses due to the uncertainty of the safety at the current dose. Imposing a waiting window to allow for more safety data to accumulate may assign the next participant to a higher and potentially more effective dose if no DLT is observed. Our aim is to create a practical tool to help trialists “look ahead” to see if imposing a waiting window would make a difference to the model’s dose recommendation.
Methods
We propose the dose transition pathways (DTP) for TITE-CRM design with possible waiting window (DTP-TITE-CRM). The DTP is a practical tool to visualize the dose recommendations for subsequent cohort of participants and was first proposed by Yap et al 2017. In DTP-TITE-CRM, the DTP projects all possible recommendations until complete follow-up is achieved. The user can also specify the maximum time for a participant to wait before being assigned to a dose.
Results
Simulations show that DTP-TITE-CRM has comparable accuracy as TITE-CRM in most scenarios in terms of identifying the MTD. In settings where the MTD is at the highest dose, or all doses are tolerable, DTP-TITE-CRM outperforms TITE-CRM. We illustrate the use of DTP-TITE-CRM in a published trial which used TITE-CRM, where imposing additional waiting time could have led to different dose decisions.
Conclusions
DTP-TITE-CRM looks ahead and enumerates dose recommendations in advance and gives participants and trialists the choice to wait or to treat immediately. This approach is particularly appealing when patient numbers are limited and when the tested agents are expected to have a tolerable toxicity profile, as it allows more participants to be treated at higher doses if safe.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
C. Yap.
Funding
National Institute for Health Research (Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74P - Tumor agnostic comparison of immunohistochemistry and next-generation sequencing in detecting ALK fusions and assessment of ALK tyrosine kinase inhibitor efficacy
Presenter: Monica Chen
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Target identification by TIME phenotypes
Presenter: Robert Seitz
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Prediction of response to palliative chemotherapy by circulating tumor DNA (ctDNA) kinetics in metastatic pancreatic cancer
Presenter: Patrick Kirchweger
Session: Cocktail & Poster Display session
Resources:
Abstract
77P - Impact of germline HLA genotypes on clinical outcomes in patients (pts) with solid tumors treated with immunotherapy
Presenter: Katerin Rojas Laimito
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - High resolution in situ analysis reveals phenotypic and functional diversification within single pancreatic tumour ducts
Presenter: Ellis Michiels
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Implementing genomic profiling as standard-of-care for glioblastoma patients
Presenter: Vincent Fougner
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Cyclic fasting-mimicking diet as a strategy to improve the efficacy of standard antitumor therapies in cancer patients
Presenter: Filippo Guglielmo Maria De Braud
Session: Cocktail & Poster Display session
Resources:
Abstract
83P - Evaluation of response-predictive biomarkers for lisavanbulin: A phase II study in patients with recurrent glioblastoma
Presenter: Juanita Lopez
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Racial disparities in phase I lung cancer clinical trials
Presenter: Rohit Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials
Presenter: Antoine Mavrikios
Session: Cocktail & Poster Display session
Resources:
Abstract